Skip to main content

Table 2 Efficacy results of the ALTER0303 trial

From: China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy

Endpoint Anlotinib arm (n = 294) Placebo arm (n = 143)
OS (months, median [range]) 9.46 (8.05–10.45) 6.37 (4.93–7.98)
HR (95% CI, P value) 0.70 (0.55–0.89, P = 0.002)
PFS (months, median [range]) 5.37 (4.40–5.63) 1.40 (1.07–1.50)
HR (95% CI) 0.25 (0.19–0.31, P < 0.001)
ORR (CR + PR) 9.18% 0.70%
DCR (CR + PR + SD) 80.95% 37.06%
  1. OS, overall survival; HR, hazard ratio; CI, confidence interval; PFS, progression-free survival; ORR, objective response rate; CR, complete response; PR, partial response; SD, stable disease; DCR, disease control rate